The effects of semaglutide, empagliflozin and their combination on the kidney sodium signal from magnetic resonance imaging: A prespecified, secondary analysis from a randomized, clinical trial

What Was Tested

This randomized controlled trial paper looks at Semaglutide.

To evaluate the effect of treatment with semaglutide and empagliflozin on the cortico-medullary sodium gradient (MCR; medulla/cortex ratio), urine sodium/creatinine ratio (UNACR), and estimated plasma volume (ePV) and to compare the MCR between persons with and without type 2 diabetes.

Who Took Part

The study group was 65 participants.

Using the 23Na magnetic resonance imaging (23Na-MRI) technique, the researchers investigated the effects of 32 weeks of treatment with semaglutide, empagliflozin or their combination on MCR in 65 participants with type 2 diabetes and high risk of cardiovascular disease.

The participants were recruited from a randomized, controlled interventional trial and further characterized by UNACR and ePV.

How the Study Was Run

The design is described as randomized.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In addition, in a cross-sectional design, the researchers compared MCR by 23Na-MRI in 12 persons with type 2 diabetes and 17 matched controls.

Data from the interventional trial were analyzed using a single, multivariate linear mixed model strategy for repeated measurements.

Data from the cross-sectional study were analyzed by fitting a linear regression model adjusted for age and sex.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Cross-Sectional Studies, Kidney, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, Hypoglycemic Agents and Benzhydryl Compounds.

Author keywords: Diabetic kidney disease, Glucagon-like peptide 1 receptor agonist, Sodium-glucose transporter 2 inhibitors and Type 2 diabetes mellitus.

What This Means in Plain Language

The paper is a randomized study of Semaglutide in 65 participants.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Journal of diabetes and its complications), a journal based in United States.

More context: the Semaglutide compound page, all human trials.